Orthogonal Mutations for Heterodimerization - Invenra Inc.

EPO published patent application EP4259194A1 for methods of orthogonal mutation-based heterodimerization. The patent covers specific amino acid mutation pairs that enable controlled assembly of two different proteins into a heterodimer while preventing unwanted homodimerization, applicable to therapeutic antibody development.

For manufacturers and biotech companies developing bispecific antibodies or therapeutic fusion proteins, this patent may restrict freedom-to-operate in EU markets for similar heterodimerization technologies. Companies should assess whether their protein engineering approaches could infringe these claims and consider licensing discussions with Invenra Inc.